UBA2 and ovarian cancer: Thus, it seems that screening diagnosis of ovarian cancer should be supplemented by GLO1, TUFT1, and UBA2 determination and assessment of the risk of loss of adequate response to chemotherapy by GLO1 mRNA expression pattern determination.